The 2019 updated EULAR/ERA-EDTA guidelines for the management of lupus nephritis. Expert comments. Part II
N. L. Kozlovskaya,
S. K. Solovyev,
E. A. Aseeva,
T. V. Popkova,
T. A. Panafidina,
E. L. Nasonov,
A. M. Lila,
A. A. Mesnyankina,
N. Yu. Nikishina https://doi.org/10.14412/1996-7012-2021-1-9-14
Abstract
The paper presents the main provisions of the updated 2019 EULAR/ERA-EDTA guidelines for the lupus nephritis (LN) therapy, which have been prepared by an international group of rheumatologists, nephrologists, morphologists, and pediatricians. Part 2 of the article discusses additional therapy, monitoring, and prognosis for LN, and the management of patients with end-stage renal failure and antiphospholipid syndrome. Attention is paid to the problem of LN and pregnancy, as well as to the management of pediatric patients with kidney damage.
About the Authors
N. L. Kozlovskaya
Peoples' Friendship University of Russia;
A.K. Eramishantsev City Clinical Hospital, Moscow Healthcare Department
Russian Federation
Russian Federation
6, Miklukho-Maklai St., Moscow 117198,
15, Lenskaya St., Moscow 129327
S. K. Solovyev
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Sergei Konstantovich Solovyev
34A, Kashirskoe Shosse, Moscow 115522
E. A. Aseeva
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
T. V. Popkova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
T. A. Panafidina
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
E. L. Nasonov
V.A. Nasonova Research Institute of Rheumatology;
Institute of Professional Education, I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Russian Federation
Department of Rheumatology Institute of Professional Education, I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
34A, Kashirskoe Shosse, Moscow 115522,
8, Trubetskaya St., Build. 2, Moscow 119991
A. M. Lila
V.A. Nasonova Research Institute of Rheumatology;
Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia
Russian Federation
Russian Federation
Department of Rheumatology Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia
34A, Kashirskoe Shosse, Moscow 115522,
1/2, Barrikadnaya St., Build. 1, Moscow 125993
A. A. Mesnyankina
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
N. Yu. Nikishina
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
References
1. Tselios K, Koumaras C, Urowitz MB, et al. Do current arterial hypertension treatment guidelines apply to systemic lupus erythematosus patients? A critical appraisal. Semin Arthritis Rheum. 2014 Feb;43(4):521-5. doi: 10.1016/j.semarthrit.2013.07.007. Epub 2013 Aug 15.
2. Van Assen S, Agmon-Levin N, Elkayam O, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2011 Mar;70(3):414-22. doi: 10.1136/ard.2010.137216. Epub 2010 Dec 3.
3. Belov BS, Solov'ev SK, Tarasova GM, Aseeva EA. Vaccination in patients with systemic lupus erythematosus: results and prospects. Nauchno-prakticheskaya revmatologiya. 2018;56(3):373-9. (In Russ.).
4. Tarasova GM, Belov BS, Bukhanova DV, et al. Study of the immunogenicity and safety of 23-valent polysaccharide pneumococcal vaccine in patients with systemic lupus erythematosus. Nauchno-prakticheskaya revmatologiya. 2018;56(4):433-8. (In Russ.).
5. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016 Aug 1;37(29):2315-81. doi: 10.1093/eurheartj/ehw106. Epub 2016 May 23.
6. Popkova TV, Alekberova ZS, Aleksandrova EN, et al. Risk factors for cardiovascular disorders and atherosclerosis in systemic lupus erythematosus. Nauchno-prakticheskaya revmatologiya. 2004;42(4):10-4. (In Russ.).
7. Popkova TV, Panafindina TA, Novikova DS, et al. The significance of inflammatory markers in the development of atherosclerosis and its complications in systemic lupus erythematosus. Nauchno-prakticheskaya revmatologiya. 2013;51(6):646-53. (In Russ.).
8. Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019 Oct;78(10): 1296-304. doi: 10.1136/annrheumdis-2019-215213. Epub 2019 May 15.
9. Arora S, Nika A, Trupin L, et al. Does systemic lupus erythematosus care provided in a lupus clinic result in higher quality of care than that provided in a general rheumatology clinic? Arthritis Care Res (Hoboken). 2018 Dec;70(12):1771-77. doi: 10.1002/acr.23569. Epub 2018 Nov 10.
10. Aseeva EA, Solov'ev SK, Popkova TV, et al. Management of patients with systemic lupus erythematosus in real clinical practice. Nauchno-prakticheskaya revmatologiya. 2019;57(2):191-6. (In Russ.).
11. Medina-Rosas J, Yap KS, Anderson M, et al. Utility of urinary Protein-Creatinine ratio and protein content in a 24-hour urine collection in systemic lupus erythematosus: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2016 Sep;68(9): 1310-9. doi: 10.1002/acr.22828. Epub 2016 Jul 29.
12. Medina-Rosas J, Gladman DD, Su J, et al. Utility of untimed single urine protein/ creatinine ratio as a substitute for 24-h proteinuria for assessment of proteinuria in systemic lupus erythematosus. Arthritis Res Ther. 2015 Oct 24;17:296. doi: 10.1186/s13075-015-0808-x.
13. Choi IA, Park JK, Lee EY, et al. Random spot urine protein to creatinine ratio is a reliable measure of proteinuria in lupus nephritis in Koreans. Clin Exp Rheumatol. Jul-Aug 2013; 31(4):584-8. Epub 2013 May 27.
14. Mahmoud GA, Zayed HS, Ghoniem SA. Renal outcomes among Egyptian lupus nephritis patients: a retrospective analysis of 135 cases from a single centre. Lupus. 2015 Mar;24(3):331-8. doi: 10.1177/0961203314567751. Epub 2015 Jan 20.
15. Hajji M, Harzallah A, Kaaroud H, et al. Factors associated with relapse of lupus nephritis: a single center study of 249 cases. Saudi J Kidney Dis Transpl. Nov-Dec 2017;28(6): 1349-55. doi: 10.4103/1319-2442.220863.
16. Bock M, Heijnen I, Trendelenburg M. Anti-C1q antibodies as a follow-up marker in SLE patients. PLoS One. 2015 Apr 16;10(4): e0123572. doi: 10.1371/journal.pone.0123572. eCollection 2015.
17. Akhter E, Burlingame RW, Seaman AL, et al. Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers. Lupus. 2011 Oct;20(12): 1267-74. doi: 10.1177/0961203311411597. Epub 2011 Aug 3.
18. Pagni F, Galimberti S, Goffredo P, et al. The value of repeat biopsy in the management of lupus nephritis: an international multicentre study in a large cohort of patients. Nephrol Dial Transplant. 2013 Dec;28(12):3014-23. doi: 10.1093/ndt/gft272. Epub 2013 Aug 24.
19. Malvar A, Pirruccio P, Alberton V, et al. Histologic versus clinical remission in proliferative lupus nephritis. Nephrol Dial Transplant. 2017 Aug 1;32(8):1338-44. doi: 10.1093/ndt/gfv296.
20. De Rosa M, Azzato F, Toblli JE, et al. A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy. Kidney Int. 2018 Oct;94(4):788-94. doi: 10.1016/j.kint.2018.05.021. Epub 2018 Jul 23.
21. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League against rheumatism and European renal AssociationEuropean dialysis and transplant association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012 Nov;71(11): 1771-82. doi: 10.1136/annrheumdis-2012-201940. Epub 2012 Jul 31.
22. Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing Guideline development, reporting and evaluation in health care. CMAJ. 2010 Dec 14;182(18):E839-42. doi: 10.1503/cmaj.090449. Epub 2010 Jul 5.
23. Song D, Wu L, Wang F, et al. The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther. 2013 Jan 15;15(1):R12. doi: 10.1186/ar4142.
24. Park MH, Caselman N, Ulmer S, et al. Complement-mediated thrombotic microangiopathy associated with lupus nephritis. Blood Adv. 2018 Aug 28;2(16):2090-94. doi: 10.1182/bloodadvances.2018019596.
25. Chel'dieva FA, Reshetnyak TM, RadenskaLopovok SG, et al. Antiphospholipid syndrome and systemic lupus erythematosus: what disease causes organ damage? Nauchnoprakticheskaya revmatologiya. 2020;58(2): 225-31. (In Russ.).
26. Yue C, Li G, Wen Y, et al. Early reninangiotensin system blockade improved shortterm and longterm renal outcomes in systemic lupus erythematosus patients with Antiphospholipid-associated nephropathy. J Rheumatol. 2018 May;45(5):655-62. doi: 10.3899/jrheum.170561. Epub 2018 Feb 15.
27. Andreoli L, Bertsias GK, Agmon-Levin N, et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2017 Mar;76(3): 476-85. doi: 10.1136/annrheumdis-2016-209770. Epub 2016 Jul 25.
28. Kosheleva NM, Mat'yanova EV, Fedorova EV, Klimenchenko NI. Pregnancy outcomes in patients with rheumatoid arthritis and systemic lupus erythematosus. Part I. Maternal outcomes. Nauchno-prakticheskaya revmatologiya. 2019;57(2):180-5. (In Russ.).
29. Koh JH, Ko HS, Kwok SK, et al. Hydroxychloroquine and pregnancy on lupus flares in Korean patients with systemic lupus erythematosus. Lupus. 2015 Feb;24(2):210-7. doi: 10.1177/0961203314555352. Epub 2014 Oct 10.
30. Koh JH, Ko HS, Lee J, et al. Pregnancy and patients with preexisting lupus nephritis: 15 years of experience at a single center in Korea. Lupus. 2015 Jun;24(7):764-72. doi: 10.1177/0961203315572715. Epub 2015 Feb 23.
31. Fischer-Betz R, Specker C, Brinks R, et al. Low risk of renal flares and negative outcomes in women with lupus nephritis Conceiving after switching from mycophenolate mofetil to azathioprine. Rheumatology (Oxford). 2013 Jun;52(6):1070-6. doi: 10.1093/rheumatology/kes425. Epub 2013 Feb 4.
32. Shilov EM, Smirnov AV, Kozlovskaya NL, editors. Nefrologiya. Klinicheskie rekomendatsii [Nephrology. Clinical guidelines]. Moscow: GEOTAR-Media; 2016. 816 p.
33. National guidelines «Diagnosis and treatment of nephritis in systemic lupus erythematosus»]. http://nonr.ru/wpcontent/uploads/2013/11
34. Elmougy A, Sarhan A, Hammad A, et al. Lupus nephritis in Egyptian children: a 16- year experience. J Nephrol. 2015 Oct;28(5):557-62. doi: 10.1007/s40620-014-0157-x. Epub 2014 Dec 10.
35. Fiorot FJ, Islabao AG, Pereira RM, et al. Disease presentation of 1312 childhoodonset systemic lupus erythematosus: influence of ethnicity. Clin Rheumatol. 2019 Oct;38(10): 2857-63. doi: 10.1007/s10067-019-04631-0. Epub 2019 Jun 13.
36. Groot N, de Graeff N, Marks SD, et al. European evidence-based recommendations for the diagnosis and treatment of childhoodonset lupus nephritis: the SHARE initiative. Ann Rheum Dis. 2017 Dec;76(12):1965-73. doi: 10.1136/annrheumdis-2017-211898. Epub 2017 Sep 6.
37. Mina R, von Scheven E, Ardoin SP, et al. Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2012 Mar;64(3):375-83. doi: 10.1002/acr.21558.
Review
For citations:
Kozlovskaya NL, Solovyev SK, Aseeva EA, Popkova TV, Panafidina TA, Nasonov EL, Lila AM, Mesnyankina AA, Nikishina NY. The 2019 updated EULAR/ERA-EDTA guidelines for the management of lupus nephritis. Expert comments. Part II. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2021;15(1):9-14. (In Russ.) https://doi.org/10.14412/1996-7012-2021-1-9-14
Views:
1187
Email this article 